HIGHLIGHTS
- who: Telles S and collaborators from the Patanjali Research Foundation, Haridwar, India have published the paper: 3:, in the Journal: (JOURNAL)
- future: The focus of future research should be the long term follow-up of patients undergoing DS therapy for psoriasis. Future Directions Hence though beneficial adverse effects of DS therapy cannot be entirely ruled out.
SUMMARY
Psoriasis is an inflammatory, autoimmune disease mediated by interleukin (IL)-17 producing Cluster of Differentiation 4 (CD4+) and T helper cells (Th) cells. The benefits of DS therapy in patients with psoriasis were determined . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.